うっ血性心不全（CHF）治療機器 - 世界市場の考察、競合情勢、市場予測（2030年）

世界のうっ血性心不全（CHF）治療機器の市場規模は、2023年に174億1,000万米ドル、2030年までに279億6,000万米ドルに達し、2024年～2030年の予測期間にCAGRで8.26％の成長が見込まれます。市場は、心血管疾患（CVDs）の罹患率の上昇、製品開発における研究開発活動の急増、これらの疾患に罹患しやすい老年人口の増加により積極的な成長を示しています。さらに、座りがちなライフスタイルや、COVID-19パンデミック中の心不全症例におけるこれらの機器の非常に大きな利点、低侵襲性の介入の人気の高まりがこれらの機器の需要をさらに押し上げ、2024年～2030年の予測期間にうっ血性心不全（CHF）治療機器市場の成長に寄与します。

うっ血性心不全（CHF）治療機器の市場力学

うっ血性心不全（CHF）治療機器市場は、さまざまな理由により製品需要が伸びています。主な要因は、心血管疾患（CVDs）の罹患率の上昇などです。

世界保健機関（WHO）（2022）が提供したデータによると、心血管疾患は世界中で主な死因となっており、この疾患群は2019年に毎年推定1,790万人の命を奪っています。さらに、WHOによる同じデータでは、CVDによる死亡の5件中4件超が脳卒中と心臓発作を主因としており、これらの死亡の3分の1は70歳未満の人々で早期に発生すると言われています。CVDによる死亡の4分の3超は中低所得国で起こっています。

European Society for Cardiology（ESC）（2022）が提供したデータによると、毎年欧州では心血管疾患（CVD）が390万人の死亡原因となっており、欧州連合（EU）では180万人以上が死亡しています。CVDによる死亡者数は、欧州では全死亡者数の約45％、EUでは37％を占めています。

さらに、WHOが欧州について提供したデータによると、CVDが死因として挙げられている死亡者数は、欧州の方が約46倍多いです。

疾病予防管理センター（CDC）によれば、2020年、冠動脈疾患（CAD）、心臓発作、糖尿病、高血圧、肥満などの特定の危険因子が心不全のリスクを高めます。

さらに、高齢患者の増加により、医療提供体制が変化し、うっ血性心不全（CHF）治療機器の需要が高まると予測されています。近年の調査「Global Population Aging 2020 Report」（国連、2020）によると、老年人口は警戒すべきペースの増加傾向にあります。2020年、世界で65歳以上の高齢者は約7億2,700万人に上りました。2050年までに、このような患者の数は倍増し、15億人に達すると予測されています。老年人口は心血管障害を引き起こしやすいため、うっ血性心不全（CHF）治療機器の増加をもたらし、うっ血性心不全（CHF）治療機器市場を押し上げると見込まれます。このように、これらすべての要因がうっ血性心不全（CHF）治療機器市場の成長を促進すると予測されます。

心血管疾患に加えて、喫煙や、脂肪、コレステロール、ナトリウムの多い食品の摂取、運動不足、アルコールの過剰摂取などの危険因子を含む座りがちなライフスタイルなどの要因は、結果として世界の心不全患者の増加につながり、うっ血性心不全（CHF）治療機器全体の需要を促進します。

上記の要因に加えて、バッテリー寿命の延長、患者モニタリングの改良、緊急時の治療効果を高める機器のプログラミングの改良など、植込み型除細動器（ICD）技術における近年のいくつかの進歩など、うっ血性心不全（CHF）治療機器の分野における技術の進歩も、うっ血性心不全（CHF）治療機器のプラス成長をもたらしている要因です。

しかし、多数の製品リコールと高いコストが、うっ血性心不全（CHF）治療機器市場成長の一定の抑制要因となる可能性があります。

当レポートでは、世界のうっ血性心不全（CHF）治療機器市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 うっ血性心不全（CHF）治療機器市場レポートのイントロダクション

第2章 うっ血性心不全（CHF）治療機器市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価
• 財務ベンチマーク

第3章 規制と特許の分析

• 米国
• 欧州
• 日本
• 中国

第4章 うっ血性心不全（CHF）治療機器市場の主な要因の分析

• うっ血性心不全（CHF）治療機器市場の促進要因
  • 心血管疾患（CVDs）の罹患率の増加
  • 製品開発における研究開発活動の急増
  • これらの疾患にかかりやすい老年人口の罹患率の増加
• うっ血性心不全（CHF）治療機器市場の抑制要因と課題
  • 高いコスト
  • 多数の製品リコール
• うっ血性心不全（CHF）治療機器市場の機会
  • 先進の機器へのニーズ
  • 新興市場をターゲットにした製品の発売

第5章 うっ血性心不全（CHF）治療機器市場のポーターのファイブフォース分析

第6章 うっ血性心不全（CHF）治療機器市場に対するCOVID-19の影響分析

第7章 うっ血性心不全（CHF）治療機器市場のレイアウト

• 製品別
  • 補助人工心臓（VAD）
  • 植込み型除細動器
  • ペースメーカー
  • 心臓再同期療法
  • その他
• エンドユーザー別
  • 病院
  • 心臓センター
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 うっ血性心不全（CHF）治療機器市場：世界の企業シェア分析 - 主要3～5社

第9章 うっ血性心不全（CHF）治療機器市場の企業と製品のプロファイル

• General Electric Company
• Boston Scientific Corporation
• Medtronic
• St. Jude Medical, Inc.
• Biotronik SE & Co. KG
• LivaNova PLC
• Shree Pacetronix Ltd.
• OSCOR Inc.
• MEDICO S.p.A.
• Lepu Medical Technology Co. Ltd.
• MicroPort Scientific Corporation
• Edwards Lifesciences
• Zoll Medical Corporation
• Vitatron
• Osypka Medical, Inc.
• Cook Medical
• Abbott
• CorWave SA
• Berlin Heart GmbH
• Jarvik Heart, Inc.

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis
• Table 3: Congestive Heart Failure (CHF) Treatment Devices Market in Global (2021-2030)
• Table 4: Congestive Heart Failure (CHF) Treatment Devices Market in Global by Product (2021-2030)
• Table 5: Congestive Heart Failure (CHF) Treatment Devices Market in Global by End User (2021-2030)
• Table 6: Congestive Heart Failure (CHF) Treatment Devices Market in Global by Geography (2021-2030)
• Table 7: Congestive Heart Failure (CHF) Treatment Devices Market in North America (2021-2030)
• Table 8: Congestive Heart Failure (CHF) Treatment Devices Market in North America by Product (2021-2030)
• Table 9: Congestive Heart Failure (CHF) Treatment Devices Market in North America by End User (2021-2030)
• Table 10: Congestive Heart Failure (CHF) Treatment Devices Market in North America by Country (2021-2030)
• Table 11: Congestive Heart Failure (CHF) Treatment Devices Market in the US (2021-2030)
• Table 12: Congestive Heart Failure (CHF) Treatment Devices Market in Canada (2021-2030)
• Table 13: Congestive Heart Failure (CHF) Treatment Devices Market in Mexico (2021-2030)
• Table 14: Congestive Heart Failure (CHF) Treatment Devices Market in Europe (2021-2030)
• Table 15: Congestive Heart Failure (CHF) Treatment Devices Market in Europe by Product (2021-2030)
• Table 16: Congestive Heart Failure (CHF) Treatment Devices Market in Europe by End User (2021-2030)
• Table 17: Congestive Heart Failure (CHF) Treatment Devices Market in Europe by Country (2021-2030)
• Table 18: Congestive Heart Failure (CHF) Treatment Devices Market in France (2021-2030)
• Table 19: Congestive Heart Failure (CHF) Treatment Devices Market in Germany (2021-2030)
• Table 20: Congestive Heart Failure (CHF) Treatment Devices Market in the United Kingdom (2021-2030)
• Table 21: Congestive Heart Failure (CHF) Treatment Devices Market in Italy (2021-2030)
• Table 22: Congestive Heart Failure (CHF) Treatment Devices Market in Spain (2021-2030)
• Table 23: Congestive Heart Failure (CHF) Treatment Devices Market in Russia (2021-2030)
• Table 24: Congestive Heart Failure (CHF) Treatment Devices Market in Rest of Europe (2021-2030)
• Table 25: Congestive Heart Failure (CHF) Treatment Devices Market in APAC (2021-2030)
• Table 26: Congestive Heart Failure (CHF) Treatment Devices Market in APAC by Product (2021-2030)
• Table 27: Congestive Heart Failure (CHF) Treatment Devices Market in APAC by End User (2021-2030)
• Table 28: Congestive Heart Failure (CHF) Treatment Devices Market in APAC by Country (2021-2030)
• Table 29: Congestive Heart Failure (CHF) Treatment Devices Market in China (2021-2030)
• Table 30: Congestive Heart Failure (CHF) Treatment Devices Market in Japan (2021-2030)
• Table 31: Congestive Heart Failure (CHF) Treatment Devices Market in India (2021-2030)
• Table 32: Congestive Heart Failure (CHF) Treatment Devices Market in Australia (2021-2030)
• Table 33: Congestive Heart Failure (CHF) Treatment Devices Market in South Korea (2021-2030)
• Table 34: Congestive Heart Failure (CHF) Treatment Devices Market in Rest of APAC (2021-2030)
• Table 35: Congestive Heart Failure (CHF) Treatment Devices Market in Rest of World (2021-2030)
• Table 36: Congestive Heart Failure (CHF) Treatment Devices Market in RoW by Product (2021-2030)
• Table 37: Congestive Heart Failure (CHF) Treatment Devices Market in RoW by End User (2021-2030)
• Table 38: Congestive Heart Failure (CHF) Treatment Devices Market in RoW by Region (2021-2030)
• Table 39: Congestive Heart Failure (CHF) Treatment Devices Market in Middle East (2021-2030)
• Table 40: Congestive Heart Failure (CHF) Treatment Devices Market in Africa (2021-2030)
• Table 41: Congestive Heart Failure (CHF) Treatment Devices Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis
• Figure 3: Congestive Heart Failure (CHF) Treatment Devices Market in Global (2021-2030)
• Figure 4: Congestive Heart Failure (CHF) Treatment Devices Market in Global by Product (2021-2030)
• Figure 5: Congestive Heart Failure (CHF) Treatment Devices Market in Global by End User (2021-2030)
• Figure 6: Congestive Heart Failure (CHF) Treatment Devices Market in Global by Geography (2021-2030)
• Figure 7: Congestive Heart Failure (CHF) Treatment Devices Market in North America (2021-2030)
• Figure 8: Congestive Heart Failure (CHF) Treatment Devices Market in North America by Product (2021-2030)
• Figure 9: Congestive Heart Failure (CHF) Treatment Devices Market in North America by End User (2021-2030)
• Figure 10: Congestive Heart Failure (CHF) Treatment Devices Market in North America by Country (2021-2030)
• Figure 11: Congestive Heart Failure (CHF) Treatment Devices Market in the US (2021-2030)
• Figure 12: Congestive Heart Failure (CHF) Treatment Devices Market in Canada (2021-2030)
• Figure 13: Congestive Heart Failure (CHF) Treatment Devices Market in Mexico (2021-2030)
• Figure 14: Congestive Heart Failure (CHF) Treatment Devices Market in Europe (2021-2030)
• Figure 15: Congestive Heart Failure (CHF) Treatment Devices Market in Europe by Product (2021-2030)
• Figure 16: Congestive Heart Failure (CHF) Treatment Devices Market in Europe by End User (2021-2030)
• Figure 17: Congestive Heart Failure (CHF) Treatment Devices Market in Europe by Country (2021-2030)
• Figure 18: Congestive Heart Failure (CHF) Treatment Devices Market in France (2021-2030)
• Figure 19: Congestive Heart Failure (CHF) Treatment Devices Market in Germany (2021-2030)
• Figure 20: Congestive Heart Failure (CHF) Treatment Devices Market in the United Kingdom (2021-2030)
• Figure 21: Congestive Heart Failure (CHF) Treatment Devices Market in Italy (2021-2030)
• Figure 22: Congestive Heart Failure (CHF) Treatment Devices Market in Spain (2021-2030)
• Figure 23: Congestive Heart Failure (CHF) Treatment Devices Market in Russia (2021-2030)
• Figure 24: Congestive Heart Failure (CHF) Treatment Devices Market in Rest of Europe (2021-2030)
• Figure 25: Congestive Heart Failure (CHF) Treatment Devices Market in APAC (2021-2030)
• Figure 26: Congestive Heart Failure (CHF) Treatment Devices Market in APAC by Product (2021-2030)
• Figure 27: Congestive Heart Failure (CHF) Treatment Devices Market in APAC by End User (2021-2030)
• Figure 28: Congestive Heart Failure (CHF) Treatment Devices Market in APAC by Country (2021-2030)
• Figure 29: Congestive Heart Failure (CHF) Treatment Devices Market in China (2021-2030)
• Figure 30: Congestive Heart Failure (CHF) Treatment Devices Market in Japan (2021-2030)
• Figure 31: Congestive Heart Failure (CHF) Treatment Devices Market in India (2021-2030)
• Figure 32: Congestive Heart Failure (CHF) Treatment Devices Market in Australia (2021-2030)
• Figure 33: Congestive Heart Failure (CHF) Treatment Devices Market in South Korea (2021-2030)
• Figure 34: Congestive Heart Failure (CHF) Treatment Devices Market in Rest of APAC (2021-2030)
• Figure 35: Congestive Heart Failure (CHF) Treatment Devices Market in Rest of World (2021-2030)
• Figure 36: Congestive Heart Failure (CHF) Treatment Devices Market in RoW by Product (2021-2030)
• Figure 37: Congestive Heart Failure (CHF) Treatment Devices Market in RoW by End User (2021-2030)
• Figure 38: Congestive Heart Failure (CHF) Treatment Devices Market in RoW by Region (2021-2030)
• Figure 39: Congestive Heart Failure (CHF) Treatment Devices Market in Middle East (2021-2030)
• Figure 40: Congestive Heart Failure (CHF) Treatment Devices Market in Africa (2021-2030)
• Figure 41: Congestive Heart Failure (CHF) Treatment Devices Market in South America (2021-2030)
• Figure 42: Market Drivers
• Figure 43: Market Barriers
• Figure 44: Marker Opportunities
• Figure 45: PORTER'S Five Force Analysis

Congestive Heart Failure (CHF) Treatment Devices Market By Product (Ventricular Assist Devices (VADS) [LVAD, RVAD, BiVAD], Implantable Cardioverter Defibrillators [Transvenous Icd, Subcutaneous Icd], Pacemakers [Implantable, External], Cardiac Resynchronization Therapy [Cardiac Resynchronization Therapy-Defibrillators (CRT-D), Cardiac Resynchronization Therapy-Pacemakers (CRT-P)], Others), By End-User (Hospitals, Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising incidence of cardiovascular diseases and rapid technological developmental activities

Global Congestive Heart Failure (CHF) Treatment Devices Market was valued at USD 17.41 billion in 2023, growing at a CAGR of 8.26% during the forecast period from 2024 to 2030 to reach USD 27.96 billion by 2030. The Congestive Heart Failure (CHF) Treatment Devices market is witnessing positive growth owing to the rising incidence of Cardiovascular Diseases (CVDs), a surge in the research and development activities in product development, increasing incidences of the aging population who are susceptible to these diseases. Moreover, due to sedentary lifestyle and extreme benefits of these devices in heart failure cases during the COVID-19 pandemic and the growing popularity of minimally invasive interventions had further pushed for the demand of these devices, thereby contributing to the growth of Congestive Heart Failure (CHF) Treatment Devices market during the forecast period from 2024-2030.

Congestive Heart Failure (CHF) Treatment Devices Market Dynamics:

The Congestive Heart Failure (CHF) Treatment Devices market is witnessing a growth in product demand owing to various reasons. The key factor includes the rising incidence of Cardiovascular Diseases (CVDs).

As per the data provided by the World Health Organization 2022, cardiovascular diseases are the leading cause of death across the globe, wherein this group of diseases accounts for an estimated 17.9 million lives each year in 2019. Furthermore, the same data by the WHO presented that over four out of five CVD deaths list strokes and heart attacks as the main cause, and one-third of these deaths are said to occur prematurely in people below 70 years of age. Over three-quarters of CVD deaths take place in low- and middle-income countries.

According to the data provided by the European Society for Cardiology (ESC) 2022, each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. They represent about 45% of all deaths in Europe and 37% in the EU.

Additionally, as per the data provided by the WHO for Europe, deaths, where CVD is listed as a cause, are about 46 times higher in Europe.

As per the Centres for Disease Control and Prevention (CDC), in 2020, certain risk factors like coronary artery disease (CAD), heart attacks, diabetes, high blood pressure, and obesity increases the risk for heart failure.

Moreover, it is predicted that the rising number of elderly patients would transform healthcare delivery and create a larger demand for Congestive Heart Failure (CHF) Treatment Devices. As per the recent survey, Global Population Aging 2020 Report (United Nations, 2020), the aging population tends to grow at an alarming pace. In 2020, there were around 727 million individuals in the world aged 65 years or older. By 2050, the figure for such patients is expected to double and reach 1.5 billion by 2050. Since the aging population is more prone to cardiovascular disorders, therefore it will give rise to an increasing of the Congestive Heart Failure (CHF) Treatment Devices, which will boost the Congestive Heart Failure (CHF) Treatment Devices market. Thus, all these factors are projected to drive the growth of the market for Congestive Heart Failure (CHF) Treatment Devices.

In addition to cardiovascular diseases, factors like a sedentary lifestyle that involves risk factors such as smoking tobacco, eating foods high in fat, cholesterol, and sodium, not enough physical activity, excessive alcohol intake, will eventually lead to an increase in heart failure cases globally, thereby driving the demand for the overall Congestive Heart Failure (CHF) Treatment Devices.

Along with the factors mentioned above, technological advancements in the field of Congestive Heart Failure (CHF) Treatment Devices such as there have been several recent advancements in implantable cardioverter-defibrillator (ICD) technology to extend battery life, improve patient monitoring, and better device programming to enhance therapy effectiveness in emergencies, which is another factor that has led to the positive growth of Congestive Heart Failure (CHF) Treatment Devices.

However, the number of product recalls and high cost may be certain limiting factors of the Congestive Heart Failure (CHF) Treatment Devices market growth.

The ongoing Coronavirus disease 2019 (COVID-19) pandemic has slightly positively impacted the market for Congestive Heart Failure (CHF) Treatment Devices as hospital admissions for COVID -19 patients were at maximum priority and the Congestive Heart Failure (CHF) Treatment Devices were used for corona-infected patients in order to provide supportive treatments. This resulted in the increased demand for Congestive Heart Failure (CHF) Treatment Devices during the pandemic. Moreover, the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape post pandemic made the resumption of regular healthcare services, which kept the demand for these products on course in the Congestive Heart Failure (CHF) Treatment Devices market.

Congestive Heart Failure (CHF) Treatment Devices Market Segment Analysis:

Congestive Heart Failure (CHF) Treatment Devices Market By Product (Ventricular Assist Devices (VADs) [LVAD, RVAD, BiVAD], Implantable Cardioverter Defibrillators [Transvenous ICD, Subcutaneous ICD], Pacemakers [Implantable, External], Cardiac Resynchronization therapy [Cardiac Resynchronization Therapy-Defibrillators (CRT-D), Cardiac Resynchronization Therapy-Pacemakers (CRT-P)], Others), By End-User (Hospitals, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the Product segment of the Congestive Heart Failure (CHF) Treatment Devices market, the Implantable Pacemakers are estimated to hold a higher share in the Congestive Heart Failure (CHF) Treatment Devices market during the forecast period (2024-2030). This can be attributed to the specific features associated with these devices.

The rapid growth of this segment can be attributed to the preference these pacemakers have over their external counterparts. In this type of device segment, the biggest trendsetter in pacemaker technology in the last few years has been the introduction of US Food and Drug Administration (FDA)-cleared MRI compatible models, as these pacemakers minimize heating potential, dislodgement, current induction, and electromagnetic interference. These allow patients to undergo MR imaging exams without harm to the device or changes to the device settings. Pacemakers without MRI-conditional use technology usually prevented patients from being able to get an MRI.

The market is driven by the factors, such as the growing aging population who are very susceptible to coronary heart disease, technological developments in pacemakers that minimize the chances of heart failure, and improved efficiency of devices. In July 2020, Abbott received FDA approval for its new generation of connected Pacemakers and defibrillator implants. The MRI-compatible Gallant devices were launched in Europe in February same year, after Abbott received a CE mark, expanding its portfolio in the Pacemakers domain.

Additionally, assistance from government bodies, favorable reimbursement, increased government expenditure for research and development, is expected to enhance the market potential in several countries. Therefore, such initiatives from the government are expected to help the market and the patients in their treatment which will drive the Congestive Heart Failure (CHF) Treatment Devices market growth.

North America is expected to dominate the overall Congestive Heart Failure (CHF) Treatment Devices Market:

Among all the regions, North America is expected to account for the largest share in the Global Congestive Heart Failure (CHF) Treatment Devices market. Factors such as the rising cases of CVDs, increased incidence of these disorders in the aging population, and improved product launches are expected to aid in the growth of the North America Congestive Heart Failure (CHF) Treatment Devices Market.

The cases of CVDs are rising constantly in North America. These cases promote the need for use of Congestive Heart Failure (CHF) Treatment Devices in disease treatment. For instance, CDC 2020, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. About 655,000 Americans die from heart disease each year-that's 1 in every 4 deaths. These cases of deaths promote more and more use of such devices for their treatment and recovery of pateients.

As per the Heart and Stroke Foundation of Canada, 2022, it is estimated that about 600,000 Canadians are living with heart failure. Congestive heart failure is on the rise as more people survive heart attacks and other acute heart conditions. As people with damaged hearts are living longer, they become more susceptible to heart failure. Moreover, according to the Canadian Chronic Disease Surveillance System, heart disease is the leading cause of disability-adjusted life years (DALYs) lost due to ill-health, disability, or early death worldwide.

Furthermore, the increased emphasis on product development activities and the high interest of device manufacturers in accessing local markets further aid in the growth of the regional markets for Congestive Heart Failure (CHF) Treatment Devices. For instance, in June 2020, Philips received FDA approval for its two new automated external defibrillators, HeartStart FR3 and HeartStart FRx.

These kinds of product launches in the local markets may drive the product demand in the market. Therefore, the interplay of various factors such as the presence of a large patient population, encouraging reimbursement policies as well as new product launches in the region is expected to boost the North America Congestive Heart Failure (CHF) Treatment Devices market during the forecast period.

Congestive Heart Failure (CHF) Treatment Devices Market Key Players:

Some of the key market players operating in the Congestive Heart Failure (CHF) Treatment Devices market include General Electric Company, Boston Scientific Corporation, Medtronic, St. Jude Medical, Inc., Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Edwards Lifesciences, Zoll Medical Corporation, Vitatron, Osypka Medical, Inc., Cook Medical, Abbott, CorWave SA, Berlin Heart GmbH, Jarvik Heart, Inc. and others.

Recent Developmental Activities in the Congestive Heart Failure (CHF) Treatment Devices Market:

In June 2022, Medtronic launched the world's smallest pacemaker to treat heart block. Micra AV with atrioventricular synchrony is the first pacemaker that can sense atrial activity without a lead or device in the upper chamber of the heart. The in-house created pacemaker is small enough to go inside the heart via a catheter. This will prove as a game-changer in the Pacemakers market.

In June 2020, Medtronic PLC announced its approval of CE Mark for Micra(TM) AV Transcatheter Pacing System (TPS), the world's smallest pacemaker with atrioventricular (AV) synchrony.

In January 2020, Abbott received CE Mark for its new implantable cardioverter defibrillator, Gallant, and cardiac resynchronization therapy defibrillator devices. The devices offer a patient preferred design having smartphone connectivity, connected applications, improved battery longevity, and MRI compatibility.

Key Takeaways from the Congestive Heart Failure (CHF) Treatment Devices Market Report Study

• Market size analysis for current Congestive Heart Failure (CHF) Treatment Devices market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Congestive Heart Failure (CHF) Treatment Devices market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global Congestive Heart Failure (CHF) Treatment Devices market.
• Various opportunities available for the other competitor in the Congestive Heart Failure (CHF) Treatment Devices market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current Congestive Heart Failure (CHF) Treatment Devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Congestive Heart Failure (CHF) Treatment Devices market growth in the coming future?

Target Audience who can be benefited from this Congestive Heart Failure (CHF) Treatment Devices Market Report Study

• Congestive Heart Failure (CHF) Treatment Devices products providers
• Research organizations and consulting companies
• Congestive Heart Failure (CHF) Treatment Devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Congestive Heart Failure (CHF) Treatment Devices
• Various End-users who want to know more about the Congestive Heart Failure (CHF) Treatment Devices market and latest technological developments in the Congestive Heart Failure (CHF) Treatment Devices market.

Frequently Asked Questions for Congestive Heart Failure (CHF) Treatment Devices Market:

1. What are Congestive Heart Failure (CHF) Treatment Devices?

Congestive Heart Failure (CHF) Treatment Devices involve a number of devices that maintain heart rhythms, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs) to treat CHF.

2. What is the market for Global Congestive Heart Failure (CHF) Treatment Devices?

Global Congestive Heart Failure (CHF) Treatment Devices Market was valued at USD 17.41 billion in 2023, growing at a CAGR of 8.26% during the forecast period from 2024 to 2030 to reach USD 27.96 billion by 2030.

3. What are the drivers for the Global Congestive Heart Failure (CHF) Treatment Devices Market?

The Congestive Heart Failure (CHF) Treatment Devices market is witnessing a positive market growth owing to the rising incidence of Cardiovascular Diseases (CVDs), a surge in the research and development activities in product development, increasing incidences of the aging population who are susceptible to these diseases. Moreover, due to the sedentary lifestyle and extreme benefits of these devices in heart failure cases during the COVID-19 pandemic and the growing popularity of minimally invasive interventions, further pushed for the demand of these devices, thereby contributing to the growth of Congestive Heart Failure (CHF) Treatment Devices market during the forecast period from 2024-2030.

4. Who are the key players operating in the Global Congestive Heart Failure (CHF) Treatment Devices Market?

Some of the key market players operating in the Congestive Heart Failure (CHF) Treatment Devices market include General Electric Company, Boston Scientific Corporation, Medtronic, St. Jude Medical, Inc., Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Edwards Lifesciences, Zoll Medical Corporation, Vitatron, Osypka Medical, Inc., Cook Medical, Abbott, CorWave SA, Berlin Heart GmbH, Jarvik Heart, Inc., and others.

5. Which region has the highest share in Congestive Heart Failure (CHF) Treatment Devices Market?

North America is expected to hold the highest share in the revenue in the Congestive Heart Failure (CHF) Treatment Devices market during the forecast period. Factors such as the rising cases of CVDs, increased incidence of these disorders in the aging population, and improved product launches are expected to aid in the growth of the North America Congestive Heart Failure (CHF) Treatment Devices Market in this region.

Table of Contents

1.Congestive Heart Failure (CHF) Treatment Devices Market Report Introduction

2.Congestive Heart Failure (CHF) Treatment Devices Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory and Patent Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Congestive Heart Failure (CHF) Treatment Devices Market Key Factors Analysis

• 4.1. Congestive Heart Failure (CHF) Treatment Devices Market Drivers
  • 4.1.1. The Rising Incidence of Cardiovascular Diseases (CVDs)
  • 4.1.2. A Surge in the Research and Development Activities in Product Development
  • 4.1.3. Increasing Incidences of the Aging Population who are Susceptible to these Diseases
• 4.2. Congestive Heart Failure (CHF) Treatment Devices Market Restraints and Challenges
  • 4.2.1. High Cost
  • 4.2.2. Higher Product Recalls Cases
• 4.3. Congestive Heart Failure (CHF) Treatment Devices Market Opportunities
  • 4.3.1. Need For Advanced Devices
  • 4.3.2. Targeting Emerging Markets for Product Launches

5. Congestive Heart Failure (CHF) Treatment Devices Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Congestive Heart Failure (CHF) Treatment Devices Market

7. Congestive Heart Failure (CHF) Treatment Devices Market Layout

• 7.1. By Product
  • 7.1.1. Ventricular Assist Devices (VADs)
    • 7.1.1.1. LVAD
    • 7.1.1.2. RVAD
    • 7.1.1.3. BiVAD
  • 7.1.2. Implantable Cardioverter Defibrillators
    • 7.1.2.1. Transvenous ICD
    • 7.1.2.2. Subcutaneous ICD
  • 7.1.3. Pacemakers
    • 7.1.3.1. Implantable
    • 7.1.3.2. External
  • 7.1.4. Cardiac Resynchronization therapy
    • 7.1.4.1. Cardiac Resynchronization Therapy-Defibrillators (CRT-D)
    • 7.1.4.2. Cardiac Resynchronization Therapy-Pacemakers (CRT-P)
  • 7.1.5. Others
• 7.2. By End User
  • 7.2.1. Hospitals
  • 7.2.2. Cardiac Centers
  • 7.2.3. Others
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. North America Congestive Heart Failure (CHF) Treatment Devices Market, by Product
    • 7.3.1.2. North America Congestive Heart Failure (CHF) Treatment Devices Market, by End User
    • 7.3.1.3. North America Congestive Heart Failure (CHF) Treatment Devices Market, by Country
    • 7.3.1.3.1. United States
    • 7.3.1.3.2. Canada
    • 7.3.1.3.3. Mexico
  • 7.3.2. Europe
    • 7.3.2.1. Europe Congestive Heart Failure (CHF) Treatment Devices Market, by Product
    • 7.3.2.2. Europe Congestive Heart Failure (CHF) Treatment Devices Market, by End User
    • 7.3.2.3. Europe Congestive Heart Failure (CHF) Treatment Devices Market, by Country
    • 7.3.2.3.1. France
    • 7.3.2.3.2. Germany
    • 7.3.2.3.3. United Kingdom
    • 7.3.2.3.4. Italy
    • 7.3.2.3.5. Spain
    • 7.3.2.3.6. Russia
    • 7.3.2.3.7. Rest of Europe
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Market, by Product
    • 7.3.3.2. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Market, by End User
    • 7.3.3.3. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Market, by Country
    • 7.3.3.3.1. China
    • 7.3.3.3.2. Japan
    • 7.3.3.3.3. India
    • 7.3.3.3.4. Australia
    • 7.3.3.3.5. South Korea
    • 7.3.3.3.6. Rest of Asia Pacific
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. RoW Congestive Heart Failure (CHF) Treatment Devices Market, by Product
    • 7.3.4.2. RoW Congestive Heart Failure (CHF) Treatment Devices Market, by End User
    • 7.3.4.3. RoW Congestive Heart Failure (CHF) Treatment Devices Market, by Country
    • 7.3.4.3.1. Middle East
    • 7.3.4.3.2. Africa
    • 7.3.4.3.3. South America

8. Congestive Heart Failure (CHF) Treatment Devices Market Global Company Share Analysis - Key 3-5 Companies

9. Congestive Heart Failure (CHF) Treatment Devices Market Company and Product Profiles

• 9.1. General Electric Company
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. Boston Scientific Corporation
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Medtronic
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. St. Jude Medical, Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Biotronik SE & Co. KG
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. LivaNova PLC
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Shree Pacetronix Ltd.
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. OSCOR Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. MEDICO S.p.A.
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. Lepu Medical Technology Co. Ltd.
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. MicroPort Scientific Corporation
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. Edwards Lifesciences
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Zoll Medical Corporation
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Vitatron
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Osypka Medical, Inc.
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. Cook Medical
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Abbott
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. CorWave SA
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. Berlin Heart GmbH
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. Jarvik Heart, Inc.
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us